Business Wire

1. Sinopia Biosciences Awarded NIGMS Grant To Advance LEADS Platform For Data-Driven Drug Discovery 12/30/2025

   Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics identified using its proprietary LEADS drug discovery platform, announced today it has been awarded a research grant from the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH), to further advance its data-driven drug discovery capabilities.

2. Zai Lab Announces Approval Of COBENFY (xanomeline And trospium chloride) In China, A First-In-Class Therapy For Schizophrenia 12/23/2025

   Zai Lab Limited today announced that China’s National Medical Products Administration (NMPA) approved the New Drug Application (NDA) for COBENFY (xanomeline and trospium chloride) for the treatment of schizophrenia in adults.

3. Beren, Through Its Subsidiary Mandos, Submits New Drug Application To U.S. FDA For Adrabetadex In Infantile-Onset NPC 12/19/2025

   Beren Therapeutics P.B.C. (“Beren”) today announced that its subsidiary Mandos LLC (“Mandos”) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for adrabetadex, an investigational therapy for the treatment of infantile-onset Niemann-Pick disease type C (NPC).

4. Meiji Seika Pharma Partners With MBC Biolabs To Strengthen Global Innovation In Drug Discovery 12/18/2025

   Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area.

5. Cartography Receives FDA Investigational New Drug (IND) Approval And Fast Track Designation For Lead Program CBI-1214 For Colorectal Cancer 12/18/2025

   Cartography Biosciences, Inc., a biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application for its lead program, CBI-1214.

6. Quantori And Expert Systems Partner To Accelerate Drug Discovery With Foundational Predictive AI Models 12/18/2025

   Quantori, a leading provider of digital transformation services and technology for the life sciences and healthcare industries, and Expert Systems, a pioneer in next-generation AI solutions, today announced a strategic collaboration focused on developing and commercializing foundational predictive models for pharmaceutical research and development.

7. Valink Therapeutics And Nona Biosciences Form Strategic Alliance To Accelerate Novel Biologics Discovery 12/17/2025

   Valink Therapeutics (“Valink”), a private biotechnology company developing next-generation therapeutics with a focus on bispecific antibody-drug conjugates (bsADCs) and complementary modalities, and Nona Biosciences (“Nona”), a global biotechnology company providing integrated solutions for biological drug discovery and development from “Idea to IND” (I to I®), today announced the formation of a strategic biologics discovery alliance.

8. Phare Bio And Basilea Announce Landmark Partnership To Develop Next-Generation Broad-Spectrum Antibiotic Using AI 12/11/2025

   Phare Bio, a biotech social venture harnessing artificial intelligence to accelerate antibiotic discovery and development, and Basilea Pharmaceutica, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today a strategic partnership to jointly develop a novel broad-spectrum antibiotic to address critical unmet needs for patients battling life-threatening infections caused by high-priority gram-negative pathogens.

9. Chemify Receives An Additional Grant To Accelerate Digital Chemistry Small-Molecule Discovery For Tuberculosis 12/10/2025

   Chemify, the deep-tech pioneer fusing chemistry, robotics, computation, and Chemputation—Chemify’s purpose-built AI to digitize molecule creation—has received additional grant funding of $1.6M from the Gates Foundation to continue the discovery of small molecules for tuberculosis (TB).

10. Agora Open Science Trust Announces Nomination Of M4K2009 As Lead Development Candidate For Pediatric Brain Cancer Therapy 12/8/2025

    Agora Open Science Trust today announced the nomination of M4K2009 as the lead development candidate for its M4K Pharma program, which applies open science to drive the development of an affordable treatment for Diffuse Intrinsic Pontine Glioma (DIPG), a rare and devastating pediatric brain cancer.